Attenuation of malignant phenotypes of breast cancer cells through eIF2α-mediated downregulation of Rac1 signaling

Hamamura,Kazunori; Minami,Kazumasa; Tanjung,Nancy; Wan,Qiaoqiao; Koizumi,Masahiko; Matsuura,Nariaki; Na,Sungsoo; Yokota,Hiroki

doi:10.3892/ijo.2014.2366

Attenuation of malignant phenotypes of breast cancer cells through eIF2α-mediated downregulation of Rac1 signaling

Authors:
- Kazunori Hamamura
- Kazumasa Minami
- Nancy Tanjung
- Qiaoqiao Wan
- Masahiko Koizumi
- Nariaki Matsuura
- Sungsoo Na
- Hiroki Yokota
View Affiliations

Affiliations: Department of Biomedical Engineering, Indiana University Purdue University Indianapolis, Indianapolis, IN 46202, USA, Department of Functional Diagnostic Science, Osaka University Graduate School of Medicine, Suita, Osaka 565-0871, Japan, Division of Medical Physics, Oncology Center, Osaka University Hospital, Osaka University Medical School, Suita, Osaka 565-0871, Japan
Published online on: April 2, 2014 https://doi.org/10.3892/ijo.2014.2366
Pages: 1980-1988

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Blocking dephosphorylation of eukaryotic translation initiation factor 2α (eIF2α) is reported to alter proliferation and differentiation of various cells. Using salubrinal and guanabenz as an inhibitory agent of dephosphorylation of eIF2α, we addressed a question whether an elevated level of phosphorylated eIF2α attenuates malignant phenotypes of triple negative breast cancer cells (TNBCs) that lack estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2. We determined effects of salubrinal and guanabenz on in vitro phenotype of 4T1 mammary tumor cells and MDA-MB-231 human breast cancer cells and evaluated their effects on in vivo tumor growth using BALB/c mice injected with 4T1 cells. The results revealed that these agents block the proliferation and survival of 4T1 and MDA-MB-231 cells, as well as their invasion and motility. Silencing eIF2α revealed that eIF2α is involved in the reduction in invasion and motility. Furthermore, salubrinal-driven inactivation of Rac1 was suppressed in the cells treated with eIF2α siRNA, and treatment with Rac1 siRNA reduced cell invasion and motility. In vivo assay revealed that subcutaneous administration of salubrinal reduced the volume and weight of tumors induced by 4T1 cells. Collectively, the results indicate that these agents can attenuate malignant phenotype and tumor growth of breast cancer cells through the eIF2α-mediated Rac1 pathway. Since salubrinal and guanabenz are known to inhibit bone resorption, this study provides a potential use of eIF2α-mediated Rac1 regulation in suppressing the growth and metastasis of breast cancer.

View Figures

View References

1.	Ron D: Translational control in the endoplasmic reticulum stress response. J Clin Invest. 110:1383–1388. 2002. View Article : Google Scholar : PubMed/NCBI
2.	Szegezdi E, Logue SE, Gorman AM and Samali A: Mediators of endoplasmic reticulum stress-induced apoptosis. EMBO Rep. 7:880–885. 2006. View Article : Google Scholar : PubMed/NCBI
3.	Hamamura K and Yokota H: Stress to endoplasmic reticulum of mouse osteoblasts induces apoptosis and transcriptional activation for bone remodeling. FEBS Lett. 581:1769–1774. 2007. View Article : Google Scholar : PubMed/NCBI
4.	Hamamura K, Goldring MB and Yokota H: Involvement of p38 MAPK in regulation of MMP13 mRNA in chondrocytes in response to surviving stress to endoplasmic reticulum. Arch Oral Biol. 54:279–286. 2009. View Article : Google Scholar : PubMed/NCBI
5.	Boyce M, Bryant KF, Jousse C, et al: A selective inhibitor of eIF2α dephosphorylation protects cells from ER stress. Science. 307:935–939. 2005.
6.	Liu CL, Li X, Hu GL, et al: Salubrinal protects against tunic-amycin and hypoxia induced cardiomyocyte apoptosis via the PERK-eIF2α signaling pathway. J Geriatr Cardiol. 9:258–268. 2012.PubMed/NCBI
7.	Drexler HCA: Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors. PLoS One. 4:e41612009. View Article : Google Scholar : PubMed/NCBI
8.	Koizumi M, Tanjung NG, Chen A, et al: Administration of salubrinal enhances radiation induced cell death of SW1353 chondrosarcoma cells. Anticancer Res. 32:3667–3674. 2012.PubMed/NCBI
9.	Osborne CK, Zhao H and Fuqua SA: Selective estrogen receptor modulators: structure, function, and clinical use. J Clin Oncol. 18:3172–3186. 2000.PubMed/NCBI
10.	De Laurentiis M, Cianniello D, Caputo R, et al: Treatment of triple negative breast cancer (TNBC): current options and future perspectives. Cancer Treat Rev. 36(Suppl 3): S80–S86. 2010.
11.	Gluz O, Liedtke C, Gottschalk N, Pusztai L, Nitz U and Harbeck N: Triple-negative breast cancer-current status and future directions. Ann Oncol. 20:1913–1927. 2009. View Article : Google Scholar : PubMed/NCBI
12.	Bosch A, Eroles P, Zaragoza R, Vina JR and Lluch A: Triple-negative breast cancer: molecular features, pathogenesis, treatment and current lines of research. Cancer Treat Rev. 36:206–215. 2010. View Article : Google Scholar
13.	Foulkes WD, Smith IE and Reis-Filho JS: Triple-negative breast cancer. N Engl J Med. 363:1938–1948. 2010. View Article : Google Scholar : PubMed/NCBI
14.	Prud’homme GJ, Glinka Y, Toulina A, Ace O, Subramaniam V and Jothy S: Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS One. 5:e138312010.PubMed/NCBI
15.	Bouquet F, Pal A, Pilones KA, et al: TGFβ1 inhibition increases the radiosensitivity of breast cancer cells in vitro and promotes tumor control by radiation in vivo. Clin Cancer Res. 17:6754–6765. 2011.
16.	Kaur P, Nagaraja GM, Zheng H, et al: A mouse model for triple-negative breast cancer tumor-initiating cells (TNBC-TICs) exhibits similar aggressive phenotype to the human disease. BMC Cancer. 12:1202012. View Article : Google Scholar : PubMed/NCBI
17.	Tsaytler P, Harding HP, Ron D and Bertolotti A: Selective inhibition of a regulatory subunit of protein phosphatase 1 restores proteostasis. Science. 332:91–94. 2011. View Article : Google Scholar : PubMed/NCBI
18.	Niknejad N, Gorn-Hondermann I, Ma L, et al: Lovastatin-induced apoptosis is mediated by activating transcription factor 3 and enhanced in combination with salubrinal. Int J Cancer. 134:268–279. 2014. View Article : Google Scholar : PubMed/NCBI
19.	Hamamura K, Furukawa K, Hayashi T, et al: Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc Natl Acd Sci USA. 102:11041–11046. 2005. View Article : Google Scholar : PubMed/NCBI
20.	Shibuya H, Hamamura K, Hotta H, et al: Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. Cancer Sci. 103:1656–1664. 2012. View Article : Google Scholar : PubMed/NCBI
21.	Sander EE and Collard JG: Rho-like GTPases: Their role in epithelial cell-cell adhesion and invasion. Eur J Cancer. 35:1302–1308. 1999. View Article : Google Scholar
22.	Wertheimer E, Gutierrez-Uzquiza A, Rosemblit C, Lopez-Haber C, Sosa MS and Kazanietz MG: Rac signaling in breast cancer: a tale of GEFs and GAPs. Cell Signal. 24:353–362. 2012. View Article : Google Scholar : PubMed/NCBI
23.	Heid I, Lubeseder-Martellato C, Sipos B, et al: Early requirement of Rac1 in a mouse model of pancreatic cancer. Gastroenterology. 141:719–730. 2011. View Article : Google Scholar : PubMed/NCBI
24.	Welch HCE, Coadwell WJ, Ellson CD, Ferguson GJ, Andrews SR, Erdjument-Bromage H, et al: P-Rex1, a Ptdlns (3,4,5)P3- and Gβγ-regulated guanine-nucleotide exchange factor for Rac. Cell. 108:809–821. 2002.
25.	Yoshizawa M, Kawauchi T, Sone M, et al: Involvement of a Rac activator, p-Rex1, in neurotrophin-derived signaling and neuronal migration. J Neurosci. 25:4406–4419. 2005. View Article : Google Scholar : PubMed/NCBI
26.	Shim JW, Hamamura K, Chen A, Wan Q, Na S and Yokota H: Rac1 mediates load-driven attenuation of mRNA expression of nerve growth factor beta in cartilage and chondrocytes. J Musculoskelet Neuronal Interact. 13:372–379. 2013.PubMed/NCBI
27.	Rosenblatt AE, Garcia MI, Lyons L, et al: Inhibition of the Rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer. Endocr Relat Cancer. 18:207–219. 2011.
28.	Yang Y, Du J, Hu Z, et al: Activation of Rac1-PI3K/Akt is required for epidermal growth factor-induced PAK1 activfation and cell migration in MDA-MB-231 brest cancer cells. J Biomed Res. 25:237–245. 2011. View Article : Google Scholar
29.	Eckhardt BL, Francis PA, Parker BS and Anderson RL: Strategies for the discovery and development of therapies for metastatic breast cancer. Nat Rev Drug Discov. 11:479–497. 2012. View Article : Google Scholar : PubMed/NCBI
30.	Van Poznak CH, Temin S, Yee GC, et al: American society of clinical oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in meta-static breast cancer. J Clin Oncol. 29:1221–1227. 2011.PubMed/NCBI
31.	Lee BL, Higgins MJ and Goss PE: Denosumab and the current status of bone-modifying drugs in breast cancer. Acta Oncol. 51:157–167. 2012. View Article : Google Scholar
32.	Marx RE: Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Sug. 61:1115–1118. 2003. View Article : Google Scholar : PubMed/NCBI
33.	He L, Lee J, Jang JH, et al: Osteoporosis regulation by salubrinal through eIF2α mediated differentiation of osteoclast and osteoblast. Cell Signal. 25:552–560. 2013.
34.	Hamamura K, Tanjung N and Yokota H: Suppression of osteoclastogenesis through phosphorylation of eukaryotic translation initiation factor 2 alpha. J Bone Miner Metab. 31:618–628. 2013. View Article : Google Scholar : PubMed/NCBI